PURASORB PLC 9015 B is a resorbable aliphatic polyester copolymer supplied for medical device manufacturing. The grade designation identifies a lactide-caprolactone copolymer in which L-lactide is the principal monomer and ε-caprolactone is the comonomer at a nominal 90:10 molar ratio; the terminal 15 is consistent with an inherent viscosity midpoint of 1.5 dL/g measured in chloroform at 0.1 g/dL and 25 °C. The suffix B distinguishes a controlled medical device grade within the PURASORB PLC series. As an absorbable synthetic polymer, the material is intended for conversion into implantable components or drug-delivery matrices after appropriate validation under ISO 13485 and ISO 10993-1. The polymer backbone contains hydrolysable ester linkages; therefore, downstream unit operations must account for moisture, shear, and residence-time effects on molecular weight retention.

How Does the 90:10 L-Lactide-ε-Caprolactone Molar Ratio Alter Clinical Performance Relative to PLLA Homopolymer?

Hydrolysis of lactide-caprolactone copolymers proceeds by water uptake and ester bond scission. A 90:10 L-lactide:ε-caprolactone composition yields a more hydrophobic chain than a 70:30 PLC grade because caprolactone sequences, although flexible, do not dominate water diffusion. The glass transition temperature is lower than that of PLLA homopolymer due to comonomer disruption of chain packing; differential scanning calorimetry per ISO 11357-2 is required for lot-specific values. Published data for this specific configuration is limited, but the general effect of adding 10 mol% ε-caprolactone is a reduction in flexural modulus and an increase in elongation at break relative to PLLA, while retaining greater tensile strength than a 70:30 copolymer. This balance is relevant for devices requiring temporary load bearing with lower brittleness than PLLA homopolymer. In comparison with poly(DL-lactide-co-glycolide) copolymers, the lactide-caprolactone backbone releases fewer acidic glycolic acid fragments; degradation is therefore less likely to produce the sharp local pH drop associated with fast-degrading PLGA implants. Quantitative degradation kinetics must be established under ISO 13781 using simulated physiological media at 37 °C and pH 7.4, because buffering conditions and test article geometry alter mass loss profiles.

Residual Monomer, Catalyst Metal, and Moisture Specification Controls

The specification framework for medical device PLC grades includes limits for residual L-lactide and ε-caprolactone monomers, tin catalyst residue, sulfated ash, heavy metals, and residual moisture. Lot release is performed under supplier-controlled methods, but the control hierarchy is intended to align with ISO 13485 documentation and ISO 10993-1 biological evaluation records. Residual monomer levels are critical because unreacted lactide and caprolactone can contribute to local tissue irritation and change melt rheology during processing. Typical release limits for comparable PURASORB PLC grades specify total residual monomers below 0.5 wt%, tin below 100 ppm, water below 0.5 wt%, and heavy metals below 10 ppm; however, the certificate of analysis for the specific PURASORB PLC 9015 B lot must be consulted because specification values are grade- and lot-specific.

Before melt processing, the polymer must be dried under vacuum or dry-air convection to reduce moisture to a level that prevents hydrolytic chain scission. Residual water above 0.05 wt% at barrel temperatures above 180 °C accelerates molecular weight loss and generates carboxylic acid end groups that further catalyze ester hydrolysis. Drying at 80 °C under vacuum for 8 h to 12 h is used in medical polymer manufacturing; however, the actual drying endpoint depends on bed depth, pellet geometry, and vacuum level. A twin-screw extruder with an L/D ratio of at least 25:1 and closed-loop gravimetric feeding is preferred to minimize residence-time distribution and control melt temperature. Processing should be performed under nitrogen purge where possible. Screw configurations with low-shear conveying elements and minimal kneading blocks are selected for resorbable aliphatic polyesters because local shear heating can exceed nominal set-point temperatures by more than 20 °C. Injection molding of the dried polymer is commonly evaluated at barrel temperatures of 160 °C to 190 °C and mold temperatures below 30 °C for amorphous or low-crystallinity parts; semicrystalline moldings require separate cooling-rate validation. Published data for this specific PURASORB PLC 9015 B configuration is limited, so process development must include measurement of in-line melt pressure, post-processing inherent viscosity, yellowness index, and residual moisture rather than relying on general PLA processing profiles. At relative humidity above 60%, open storage of dried pellets should be limited to less than 30 min to avoid moisture regain.

When Lot-Specific Rheometry Replaces Single-Point Melt Flow Data

Single-point melt flow index is not an adequate release or process control tool for this polymer because the molecular weight distribution and moisture content of the dried resin shift the shear-rate dependence of viscosity. Capillary rheometry at 170 °C, 180 °C, and 190 °C with die diameters in the range of 1 mm to 2 mm provides shear viscosity data for extrusion screw and die design. Oscillatory parallel-plate rheometry per ISO 6721-10 gives complex viscosity and storage modulus under small-amplitude conditions; the crossover frequency of storage and loss moduli is a useful indicator of molecular weight distribution breadth. A decrease in complex viscosity at 1 rad/s of more than 30% after drying indicates hydrolytic degradation or excessive thermal exposure. The lot-specific activation energy of viscous flow, calculated from an Arrhenius fit over the processing window, should be combined with in-line melt pressure transducers and residence-time distribution data to set alarm limits on a twin-screw extruder. Thermogravimetric analysis under nitrogen per ISO 11358-1 is used to establish the onset of mass loss; extrapolated onset temperatures below 250 °C are generally avoidable in melt processing.

The principal comparator polymers within the resorbable medical device portfolio differ by comonomer type and ratio. Poly(L-lactide) homopolymer has higher crystallinity and higher tensile modulus, but its slow degradation may extend beyond 24 months in vivo depending on implant geometry and sterilization history. PURASORB PLC 7015, with a nominal 70:30 L-lactide:ε-caprolactone ratio, is more elastomeric and degrades more rapidly than the 90:10 composition because caprolactone-rich segments reduce crystallinity and increase water mobility. Poly(DL-lactide-co-glycolide) grades containing glycolide degrade faster than lactide-caprolactone copolymers of similar molecular weight and are used where short residence time is required. The 90:10 PLC grade therefore occupies a middle position: lower flexural modulus and lower brittleness than PLLA, slower hydrolysis and higher stiffness than 70:30 PLC, and slower mass loss than PLGA. The absence of glycolide units in PURASORB PLC 9015 B reduces the burst release of glycolic acid and the associated acute pH drop seen in some PLGA matrices. These differences are measurable by ASTM D638 tensile testing, ISO 178 flexural testing, and ISO 13781 degradation studies; absolute values depend on orientation, residual monomer, and specimen conditioning.

Sterilization-Induced Molecular Weight Loss and Its Influence on Finished Device Requirements

Ethylene oxide, gamma irradiation, and electron beam sterilization each affect the molecular weight of lactide-caprolactone copolymers differently. Gamma irradiation at doses of 25 kGy to 40 kGy produces free radicals that can reduce inherent viscosity and generate discoloration; the effect is greater in amorphous regions and at higher radiation doses. Electron beam sterilization delivers dose over shorter time periods, reducing oxidative exposure but still producing radical-mediated chain scission. Ethylene oxide cycles at temperatures near 45 °C to 55 °C with high relative humidity can hydrate the polymer and initiate hydrolysis before implantation; therefore, post-sterilization drying and residual ethylene oxide limits per ISO 10993-7 must be evaluated. The final device specification should not assume that pre-sterilization inherent viscosity equals post-sterilization inherent viscosity. A loss of 0.1 dL/g to 0.3 dL/g after terminal sterilization is often observed in resorbable aliphatic polyesters when irradiation is applied without free-radical scavengers or vacuum packaging; published data for this specific grade is limited. Because the 90:10 copolymer has a higher glass transition than 70:30 PLC, room-temperature storage after sterilization is less likely to cause shape distortion; nonetheless, devices must be stored in moisture-barrier packaging at controlled temperatures below 25 °C.

Application development for PURASORB PLC 9015 B is not a direct substitution of PLLA or PLGA. For absorbable medical device components such as sutures, clips, or drug-eluting matrices, material selection must be coupled to the final sterilization method, the intended degradation profile, and the required mechanical function. A twin-screw compounding trial with the dried resin should map the operating window by measuring inherent viscosity before and after processing, melt pressure at the die, and color change after multiple residence times. Injection-molded samples should then be conditioned per ISO 291 and evaluated for tensile properties per ASTM D638 and flexural properties per ISO 178. Degradation screening in phosphate-buffered saline at 37 °C and pH 7.4 should include pH monitoring and inherent viscosity decay, with timepoints at 1 week, 4 weeks, 12 weeks, and 26 weeks. When the device is intended for long-term implantation, the full biological evaluation under ISO 10993-1, including implantation and subchronic systemic toxicity endpoints, is required. The processing window is narrow; lot-to-lot variation in comonomer distribution may shift the semicrystalline morphology, and therefore process validation must include worst-case lots with the lowest and highest inherent viscosity within the supplier's release specification.